Lung cancer patients with high programmed cell death-ligand 1 (PD-L1) expression in tumor cells and <i>epidermal growth factor receptor</i> (<i>EGFR</i>) mutations are rare, but there is no clinical standard for which treatment such patients should receive. This evidence concerns the gene CD274 and lung cancer.